CMA won't launch a full market investigation of streaming and the music industry - Music Ally
Antitrust Developments in the Pharma Sector, Part II - Competition Law Insight
Four drug companies accused of illegal market sharing
Pfizer fined $106M for 2600% price hike on epilepsy drug
U.K. authorities say Actavis broke competition law with 'excessive and unfair prices' on a generic | Fierce Pharma
CMA fines Advanz over 'excessive and unfair' pricing of thyroid drug - PharmaTimes
Landmark ruling strikes down CMA decision on excessive and unfair pricing
UK Watchdog Group Accuses Pfizer, Flynn Pharma of Price Gouging on Epilepsy Drug | BioSpace
UK Regulator Fines Pharma Companies for 10,000% Drug Price Increase | BioSpace
Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing :: Pink Sheet
CMA Investigation Into Pharmaceutical Industry For Steep Price Increase
Pricing of oral generic cancer medicines in 25 European countries; findings and implications - GaBI Journal
Antitrust Developments in the Pharma Sector – Part I, Competition Law Insight
Pfizer wins appeal against CMA fine over epilepsy drug price - Pharmaceutical Technology
Sign this petition to help bring down generic drug prices | Addison's Disease Self-Help Group
UK's CMA Goes After Advanz, Morningside And Alliance On Nitrofurantoin :: Generics Bulletin
U.K. watchdog smacks Pfizer with record fine, citing a 2,600% price hike | Fierce Pharma
COVID-19: sales and pricing practices during coronavirus outbreak - GOV.UK
CMA fines pharma companies £45 million - Press releases - GOV.UK
competition Archives -
UK's CMA Issues £35m In Fines Over Prochlorperazine :: Pink Sheet
How can competition authorities tackle price rises in a crisis? - Economics Observatory
UK's CMA Issues Fines Over Fludrocortisone :: Medtech Insight
PDF) The economics of potential price gouging during Covid-19 and the application to complaints received by the CMA
